Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it brought discredit on the pharma industry. Accused of “warming the market” for a ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

EBITDA before special items decreases to 4.085 billion euros (minus 7.4 percent) / Moderate decline in sales (Fx & p adj.) at ...

Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron’s proposal to add additional ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...